BV-R2 combination shows survival benefit across high-risk subgroups.
Martina Nasralla, PharmD Candidate
Advertisement
Articles by Martina Nasralla, PharmD Candidate
Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates.
Intravenous immunoglobulin (IVIG) is a vital treatment for immunodeficiency and autoimmune disorders, with diverse mechanisms, brand-specific differences, and patient-centered considerations shaping safe and effective use.
Though new treatments offer hope, careful monitoring and understanding of risks remain essential for their success.
Advertisement
Latest Updated Articles
Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic BreakthroughsPublished: August 6th 2025 | Updated:
IVIG Therapy: Mechanisms, Formulations, and Key Considerations for Safe and Effective UsePublished: August 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5
